methyl 6-[[4-[2-fluoro-4-[[1-[(4-fluorophenyl)aminocarbonyl]cyclopropanecarbonyl]amino]phenoxy]-6-methoxy-7-quinolyl]oxy]hexanoate | 1372671-46-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 6-[[4-[2-fluoro-4-[[1-[(4-fluorophenyl)aminocarbonyl]cyclopropanecarbonyl]amino]phenoxy]-6-methoxy-7-quinolyl]oxy]hexanoate
• 英文别名: Methyl 6-[4-[2-fluoro-4-[[1-[(4-fluorophenyl)carbamoyl]cyclopropanecarbonyl]amino]phenoxy]-6-methoxyquinolin-7-yl]oxyhexanoate；methyl 6-[4-[2-fluoro-4-[[1-[(4-fluorophenyl)carbamoyl]cyclopropanecarbonyl]amino]phenoxy]-6-methoxyquinolin-7-yl]oxyhexanoate
• CAS: 1372671-46-9
• 化学式: C₃₄H₃₃F₂N₃O₇
• 分子量: 633.649
• InChiKey: BGMYAMLMUMIQCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  46
• 可旋转键数：
  15
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  125
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  methyl 6-[[4-[2-fluoro-4-[[1-[(4-fluorophenyl)aminocarbonyl]cyclopropanecarbonyl]amino]phenoxy]-6-methoxy-7-quinolyl]oxy]hexanoate 在 盐酸羟胺 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 以207 mg的产率得到N1′-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
  参考文献：
  名称：

  Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof

  摘要：

  本发明提供了一种含有喹啉基羟肟酸化合物，如式（I）所示，同时还揭示了该化合物的制备方法及其用途，以及含有该含有喹啉基羟肟酸化合物的药物组合物。这些化合物是蛋白激酶和/或组蛋白去乙酰化酶的抑制剂，可用于治疗由蛋白激酶和/或组蛋白去乙酰化酶异常活动引起的疾病，例如肿瘤等。

  公开号：

  US20140221425A1
• 作为产物：
  描述：

  4-(4-amino-2-fluorophenyloxy)-6-methoxy-7-hydroxyquinoline hydrobromide 在 4-二甲氨基吡啶 、 caesium carbonate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 6-[[4-[2-fluoro-4-[[1-[(4-fluorophenyl)aminocarbonyl]cyclopropanecarbonyl]amino]phenoxy]-6-methoxy-7-quinolyl]oxy]hexanoate
  参考文献：
  名称：

  Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof

  摘要：

  本发明提供了一种含有喹啉基羟肟酸化合物，如式（I）所示，同时还揭示了该化合物的制备方法及其用途，以及含有该含有喹啉基羟肟酸化合物的药物组合物。这些化合物是蛋白激酶和/或组蛋白去乙酰化酶的抑制剂，可用于治疗由蛋白激酶和/或组蛋白去乙酰化酶异常活动引起的疾病，例如肿瘤等。

  公开号：

  US20140221425A1

文献信息

• QUINOLINYL-SUBSTITUTED CARBOXYLIC ACID COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
  申请人：Beijing Konruns Pharmaceutical Co., Ltd.

  公开号：EP3530654A1

  公开（公告）日：2019-08-28

  The present application provides a quinolyl-substituted carboxylic acid compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, as well as a method for preparing the compound, a use of the compound, and a formulation containing the quinolyl-substituted carboxylic acid compound or the pharmaceutically acceptable salt thereof. This type of compounds are inhibitors for AXL and/or VEGFR2 protein kinase, and can be used to treat diseases caused by abnormality of the two protein kinases, such as, tumor, etc.;

  本申请提供了一种如式（I）所示的喹啉基取代的羧酸化合物或其药学上可接受的盐，以及该化合物的制备方法、该化合物的用途和含有该喹啉基取代的羧酸化合物或其药学上可接受的盐的制剂。这类化合物是 AXL 和/或 VEGFR2 蛋白激酶的抑制剂，可用于治疗由这两种蛋白激酶异常引起的疾病，如肿瘤等；
• Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same
  申请人：BEIJING KONRUNS PHARMACEUTICAL CO., LTD.

  公开号：US10723701B2

  公开（公告）日：2020-07-28

  The present application provides a quinolyl-substituted carboxylic acid compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, as well as a method for preparing the compound, a use of the compound, and a formulation containing the quinolyl-substituted carboxylic acid compound or the pharmaceutically acceptable salt thereof. This type of compounds are inhibitors for AXL and/or VEGFR2 protein kinase, and can be used to treat diseases caused by abnormality of the two protein kinases, such as, tumor, etc.

  本申请提供了一种如式（I）所示的喹啉基取代的羧酸化合物或其药学上可接受的盐，以及该化合物的制备方法、该化合物的用途和含有该喹啉基取代的羧酸化合物或其药学上可接受的盐的制剂。这类化合物是 AXL 和/或 VEGFR2 蛋白激酶的抑制剂，可用于治疗由这两种蛋白激酶异常引起的疾病，如肿瘤等。
• HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF
  申请人：Beijing Konruns Pharmaceutical Co., Ltd.

  公开号：EP2769976B8

  公开（公告）日：2017-12-13
• QUINOLYL-SUBSTITUTED CARBOXYLIC ACID COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION OF THE SAME, AND USE OF THE SAME
  申请人：BEIJING KONRUNS PHARMACEUTICAL CO., LTD.

  公开号：US20190256470A1

  公开（公告）日：2019-08-22

  The present application provides a quinolyl-substituted carboxylic acid compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, as well as a method for preparing the compound, a use of the compound, and a formulation containing the quinolyl-substituted carboxylic acid compound or the pharmaceutically acceptable salt thereof. This type of compounds are inhibitors for AXL and/or VEGFR2 protein kinase, and can be used to treat diseases caused by abnormality of the two protein kinases, such as, tumor, etc.;
• Crystalline Form of Compound, Method for Preparing the Same, Pharmaceutical Composition and Use
  申请人：Beijing Konruns Pharmaceutical Co., Ltd.

  公开号：US20220259152A1

  公开（公告）日：2022-08-18

  The present disclosure relates to the field of pharmaceutical technology, providing three crystalline forms, i.e., a crystalline form AB, a crystalline form M and a crystalline form F, of the compound 6-[[4-[2-fluoro-4-[[1-[(4-fluorophenyl)aminoformyl]cyclopropanecarbonyl]-amino]phenoxy]-6-methoxy-7-quinolyl]oxy]hexanoic acid for treatment of diseases related to protein kinases AXL and/or VEGFR2. The present disclosure also provides methods for preparing these three crystalline forms and pharmaceutical compositions comprising these three crystalline forms. The crystalline form AB, the crystalline form M and the crystalline form F of the present disclosure all have good chemical stability, and the preparation processes of the three crystalline forms of the present disclosure are simple for implementation with high product yield and purity, allowing stable and mass production that facilitates promotion and application.